AstraZeneca (NYSE: AZN) reported Q1 EPS of $1.05, $0.12 better than the analyst estimate of $0.93. Revenue for the quarter came in at $6.35 billion versus the consensus estimate of $5.95 billion.

Financial guidance for FY 2020 is unchanged. Total Revenue is expected to increase by a high single-digit to a low double-digit percentage and Core EPS is expected to increase by a mid- to high-teens percentage. AstraZeneca recognises the heightened risks and uncertainties from the impact of COVID-19 referred to above.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.